Neurology

Are immune checkpoint inhibitors safe for MS patients with cancer?

November 27, 2024

Study design: This multi-institutional, retrospective study involving 66 patients with MS being treated with immune checkpoint inhibitors (ICIs) for various cancers assessed the prevalence of MS activity and immune-related adverse events (irAEs) following ICI treatment. Data were collected from seven large academic centers, focusing on demographics, MS and cancer history, treatments, and outcomes.

Results: Among the 66 patients (median age 66 years, 73% female), 35% had lung cancer, 21% had melanoma, and the remainder had other cancers. During a median follow-up of 11.7 months, 3% experienced MS relapse or MRI activity, while 5% had neurologic irAEs and 32% had non-neurologic irAEs. At the last follow-up, 38% of patients had partial or complete cancer remission, and 53% were deceased.

Impact on clinical practice: The findings suggest that ICIs can be safely used in older MS patients with cancer, with low rates of MS exacerbation and neurologic irAEs.

Source:

Quinn CM, et al. (2024, November 14). Neurology. Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications. https://pubmed.ncbi.nlm.nih.gov/39541548/